CRESCENT BIOPHARMA, INC. (CBIO) research
CRESCENT BIOPHARMA, INC.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $14.32
- As of
CRESCENT BIOPHARMA, INC. (CBIO): 3 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.
As of . Source: SEC EDGAR filings for CBIO. Method and limitations.
Share the CBIO intelligence card
See the full CBIO dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CBIO on one page. Preview it with sample data, then open it live with a free account.
Preview the CBIO dossierActive signals for CBIO
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +61% to CBIO (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 8.7%, EPS $-0.74 vs $-0.8109 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 174.2% - EPS $-4.93 vs $-1.7978 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 37.2% - EPS $-1.27 vs $-2.0216 estimate
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 79.0% - EPS $-0.54 vs $-2.5666 estimate
FREE, NO ACCOUNT
Every signal on CBIO, as it fires
You are seeing 5 of 6 signals recorded on CBIO since 2026-05-29.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CBIO (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP G2545C104 · 2026Q2 | $7.3M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP G2545C104 · 2026Q2 | $5.4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP G2545C104 · 2026Q2 | $3.4M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CBIO
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
CBIO against its peers
CBIO's operating margin of -1407.5% ranks in the 22nd percentile of 15 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | CBIO | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.8M USD | 7.3M USD | 53 | 19 |
| Operating margin | -1407.5% | -91.4% | 22 | 15 |
| Net margin | -1419.6% | -113.8% | 22 | 15 |
| Return on equity | -75.8% | -34.8% | 26 | 20 |
Peers (23): NGNE, MNPR, OCS, EPRX, ALT, PRME, CAPR, PBYI, YDES, VALN, ALLO, MPLT, AUTL, RGNX, ARVN, CTNM, CTMX, OVID, CRMD, PHAT, ASMB, ENTX, IRWD. Left out: RLFTY (no annual filing), DRUG (period gap). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (CBIO: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more CBIO signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to CBIOand get the insider, 13F, options, and confluence read in one view.